Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Endocrinology | US/EU | 2017

Login to access report north_east
Contact sales account_box

Recent launches of Merck & Co.’s Lusduna (insulin glargine) in Europe, and Eli Lilly/Boehringer Ingelheim’s Basaglar (insulin glargine) in the United States, have expanded the non-innovator sector of the endocrinology market. Uptake of these products, as well as that of competing insulins and human growth hormone biologics including Omnitrope and Genotropin, will depend on the prescribing behavior of endocrinologists. For this reason, it is critical that manufacturers/marketers of insulin and somatropin biosimilars and brands understand which factors influence endocrinologists’ opinions, actions, and expectations. To this end, Decision Resources Group conducted primary market research with endocrinologists in France, Germany, and the United States.

Questions answered:

  • Have endocrinologists received recommendations to use biosimilars?
  • Are endocrinologists switching patients from reference brands to biosimilars?
  • What factors do endocrinologists consider when choosing among competing biosimilars?
  • How are insulin biosimilars and Omnitrope performing, and what are endocrinologists’ expectations for their future uptake?
  • What are the key drivers and barriers to uptake of insulin and somatropin biosimilars?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Boehringer Ingelheim
  • Eli Lilly
  • Merck & Co.
  • Novo Nordisk
  • Sanofi

Key drugs mentioned:

  • Apidra
  • Basaglar/Abasaglar
  • Genotropin
  • Humalog
  • Humatrope
  • Lantus
  • Levemir
  • Lusduna Nexvue/Lusduna
  • Norditropin
  • NovoLog/NovoRapid
  • Nutropin
  • Omnitrope
  • Saizen
  • Toujeo
  • Tresiba
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
north_east
Report
Insomnia – Current Treatment – Current Treatment: Physician Insights – Insomnia (EU5)
Insomnia is a common sleep disorder characterized by difficulty initiating or maintaining sleep, leading to impaired daytime functioning. Its management is highly personalized, with clinicians…
north_east
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
north_east
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
north_east
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east